Status:
UNKNOWN
Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial
Lead Sponsor:
Erasme University Hospital
Collaborating Sponsors:
Fonds Erasme pour la Recherche Médicale
Conditions:
Coronavirus
Respiratory Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Background: A novel Coronavirus (SARS-CoV-2) described in late 2019 in Wuhan, China, has led to a pandemic and to a specific coronavirus-related disease (COVID-19), which is mainly characterized by a ...
Detailed Description
Rationale for the study The cellular entry of the SARS-CoV-2 can result in a functional reduction of ACE2 activity and this could lead to an increased activity of the Ang II/AT1 axis and decreased lev...
Eligibility Criteria
Inclusion
- Age \> 18 years old
- Expected ICU stay of \> 48 hours
- Bilateral Viral Pneumonia
- Orotracheal intubation from less than 24 hours
- Confirmed or highly suspected COVID-19
Exclusion
- Patients with cancer (all stages) diagnosis
- Severe hemodynamic instability (need of vasopressors \>1 mcg/Kg/min to maintain a MAP \> 65 mmHg)
- Pregnant women
- Immunocompromised patients
- Limitations of care
- Inclusion in any other interventional trial
Key Trial Info
Start Date :
December 30 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 15 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04332666
Start Date
December 30 2021
End Date
June 15 2023
Last Update
August 2 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.